ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,870.62
      -1.32%
      US Tech 100
      19,880.00
      -2.30%
      Dow Jones
      43,444.99
      -0.70%
      Brent Oil
      71.25
      0.00%
      Bitcoin
      90,349.16
      -0.26%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NYSE
      6. GSK plc (GSK)

      7. GSK plc (GSK) News

      GSK plc

      GSK plc (GSK)

      Goldseek Resources Inc
      Gsk Plc
      33.35
      -1.04
      (-3.02%)
      Closed November 17 4:00PM
      Delayed by 15 minutes
      33.35
      0.00
      (0.00%)
      After Hours: 7:44PM
      Delayed by 15 minutes

      Professional-Grade Tools, for Individual Investors.

      Premium

      GSK News

      Official News Only

      Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
      Edgar (US Regulatory)
      November 14 2024
      GSK (-3.02%)

      Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
      Edgar (US Regulatory)
      October 30 2024
      GSK (-3.02%)

      Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
      Edgar (US Regulatory)
      October 30 2024
      GSK (-3.02%)

      Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
      Edgar (US Regulatory)
      October 17 2024
      GSK (-3.02%)

      Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
      Edgar (US Regulatory)
      October 16 2024
      GSK (-3.02%)

      Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
      Edgar (US Regulatory)
      October 16 2024
      GSK (-3.02%)

      Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
      Edgar (US Regulatory)
      October 15 2024
      GSK (-3.02%)

      Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
      Edgar (US Regulatory)
      October 15 2024
      GSK (-3.02%)

      Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
      Edgar (US Regulatory)
      September 24 2024
      GSK (-3.02%)

      GSK Discussion

      View Posts
      Monksdream Monksdream 2 months ago
      GSK up and down but mostly up
      👍️0
      Monksdream Monksdream 9 months ago
      GSK new 52 week high
      👍️0
      Monksdream Monksdream 10 months ago
      GSK new 52 week high
      👍️0
      Monksdream Monksdream 10 months ago
      GSK new 52 week high
      👍️ 1
      1jas 1jas 1 year ago
      has anybody here seen that enzolytics pharm announced that they have a cure for hiv/aids yesterday.
      👍️0
      MrHankey MrHankey 1 year ago
      Does the name Christian Lamarco (www.culperresearch.com) mean anything to you?
      If not, you should know that this "activist investor" (aka "short") has requested through FOIA from the FDA for the below information. Prepare for a hit piece and a stock drop.

      "Requesting copies of the letter and/or all communications from the FDA to GSK requesting the withdrawal of GSK's Blenrep from the market in the US, as widely reported in November 2022."

      https://www.fda.gov/media/170006/download
      👍️0
      Magnum7419 Magnum7419 1 year ago
      i am in 100@ 34.56 :)
      👍️0
      Magnum7419 Magnum7419 1 year ago
      GSK #1 pick!!
      👍️0
      jondoeuk jondoeuk 2 years ago
      Post hoc analysis shows that biomarker correlates with response to NY-ESO-1 TCR-T cells in patients with synovial sarcoma https://www.nature.com/articles/s41467-022-32491-x
      👍️0
      BottomBounce BottomBounce 2 years ago
      $GSK Total Debt is $22.11 Billion // $8.00 should be trading
      👍️0
      rosemountbomber rosemountbomber 2 years ago
      Anyone know how we will calculate our cost basis in Haleon?
      👍️0
      ruke ruke 2 years ago
      So, why shares aren't realy mooning in pre-market? Isn't that strange?
      👍️0
      jondoeuk jondoeuk 2 years ago
      Complete Responses in 100% of dMMR Rectal Cancer With Neoadjuvant PD-1 Inhibition https://www.medpagetoday.com/meetingcoverage/asco/99071
      👍️0
      jondoeuk jondoeuk 2 years ago
      Lete-Cel ASCO data https://www.cgtlive.com/view/lete-cel-exhibits-anti-tumor-activity-long-median-pfs-patients-myxoid-round-cell-liposarcoma

      👍️0
      jondoeuk jondoeuk 3 years ago
      The company has updated the master protocol for their next generation constructs to include a third arm with GSK4427296 https://clinicaltrials.gov/ct2/show/NCT04526509

      This uses LYEL's Epi-R https://lyell.com/our-platforms
      👍️0
      4MVault 4MVault 3 years ago
      GSK Should buy ATOS
      👍️0
      jondoeuk jondoeuk 3 years ago
      New NY-ESO-1 TCR-T data https://jitc.bmj.com/content/7/1/276

      From it: ''These data provide an initial rationale as to how tumors with histologies resistant to checkpoint blockade can be successfully targeted with adoptive T-cell therapy. Furthermore, these data are the first to demonstrate successful infiltration of solid tumors by SPEAR T cells, which are able to kill tumor cells. Our data also suggest that antigen loss or alterations in the expression of antigen processing proteins are not primary mechanisms of resistance. Moreover, the therapeutic efficacy may be enhanced through use of a high dose fludarabine-containing preparative lymphodepletion regimen, by promoting greater engraftment at the tumor site, and through modulation of TAM.''
      👍️0
      jondoeuk jondoeuk 3 years ago
      They have shared some preclinical data https://www.sec.gov/Archives/edgar/data/1806952/000119312521172500/d168165ds1.htm
      👍️0
      jondoeuk jondoeuk 3 years ago
      Preclinical data from another group: ''Hepatocellular carcinoma (HCC) is responsible for most of primary liver cancer cases and is the sixth most common cancer in the world with a general 5 year survival rate of 18% due to lack of effective therapy. Adoptive T-cell therapy (ACT) with T-cell receptor–engineered T-cell (TCR-T) against HCC-associated antigen a-fetoprotein (AFP), can redirect human T cells to recognize and kill HCC tumor cells.

      However, the clinical efficacy of TCR-T therapy is dependent on the proper expansion, in vivo persistence of T cells that is markedly reduced due to exhaustion-associated dysfunction, and activation induced cell death. To improve persistence of TCR-T cells without modifying TCR affinity, we engineered TCR-T cells to overexpress c-Jun, an AP-1 transcription factor associated with T cell development and activation. In this study, we showed that TCR-T cells overexpressing c-Jun have enhanced expansion capacity in culture, improved cytokine production against HepG2 tumor cells without altering their cytotoxic potential.

      Interestingly TCR-T cells overexpressing c-Jun showed resistance to activation induced cell death with decreased expression of inhibitory receptors after stimulation with HepG2 tumor cells. Thus, c-Jun overexpression could be a potential therapeutic agent to enhance the anti-tumor efficacy of TCR-T cells against HCC.''

      https://virtual.aai.org/aai/2021/virtual-immunology-2021/317351/mohamed.hussein.the.role.of.c-jun.in.enhancing.tcr-t.function.in.treatment.of.html
      👍️0
      jondoeuk jondoeuk 3 years ago
      Some more info https://lyell.com/our-platforms

      👍️0
      stillness0007 stillness0007 4 years ago
      GSK V TEVA question. The panel of judges heard the case on Feb 23rd. Am I right to understand, usually a decision is made 3-4 months after that? Cause some are saying by end of 2022, which makes no sense to me.
      👍️0
      testing4covid testing4covid 4 years ago
      Achiko AG: The One Ecosystem that Takes a ‘Swiss Cheese’ Approach to COVID-19

      Great article on an upcoming testing technology:

      https://sponsored.bloomberg.com/news/sponsors/features/next-tech-stock/the-next-big-thing-in-health-tech/?adv=33197&prx_t=wmcGAAAAAAUk0NA&prx_ro=s&sref=GS2dzBte



      👍️0
      whytestocks whytestocks 4 years ago
      Breaking News: $GSK Investors Wish They Could Vote These 2 Healthcare CEOs Out

      One of the best things about a democracy is getting to vote out representatives who let us down. As shareholders, it's much harder to express dissatisfaction in management without just selling shares, since you may really like the business despite management.  But some investors might ...

      Read the whole news GSK - Investors Wish They Could Vote These 2 Healthcare CEOs Out
      👍️0
      jondoeuk jondoeuk 4 years ago
      Decitabine has been shown to induce cancer-testis antigen expression https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0139221
      👍️0
      jondoeuk jondoeuk 4 years ago
      SITC

      Decitabine gene modulation sensitizes human non–small cell lung cancer (NSCLC) to NY-ESO-1 TCR immunotherapy (letetresgene autoleucel; GSK3377794) in vivo

      Modeling the efficacy of NY-ESO-1 TCR T cells (letetresgene autoleucel; GSK3377794) in patients with synovial sarcoma: correlations of response with transduced cell kinetics and biomarkers

      Final analysis of the Phase 1 trial of NY-ESO-1–specific T-cell receptor (TCR) T-cell therapy (letetresgene autoleucel; GSK3377794) in patients with advanced synovial sarcoma (SS)
      👍️0
      jondoeuk jondoeuk 4 years ago
      Going forward, I would like them to transduce half of the CD4+ T-cells with an NY-ESO-1 specific MHC II restricted TCR [1], and the other half to co-express a CD8a. Combining both CD4+ and CD8+ can induce bystander killing of antigen-negative cancer cells [2,3]. Also, some of the CD4+ can show tumoricidal activity by their own means irrespective of MHC II expression [4-7].

      Refs:
      1 https://www.nejm.org/doi/full/10.1056/nejmoa0800251
      2 https://rupress.org/jem/article/207/11/2469/40645/Bystander-killing-of-cancer-requires-the
      3 https://www.nature.com/articles/srep14896
      4 https://cancerres.aacrjournals.org/content/70/21/8368.long
      5 https://rupress.org/jem/article/154/3/952/49262/Eradication-of-disseminated-murine-leukemia-by
      6 https://rupress.org/jem/article/207/3/637/40473/Tumor-reactive-CD4-T-cells-develop-cytotoxic
      7 https://www.cell.com/immunity/fulltext/S1074-7613(00)80218-6
      👍️0
      jondoeuk jondoeuk 4 years ago
      Lyell plan to use defined cell populations [1], improve ex vivo expansion [2-4], and a novel co-stim [5].

      Refs:
      1 https://www.nature.com/articles/leu2015247
      2 https://www.sciencedirect.com/science/article/abs/pii/S1535610820302543
      3 https://cancerres.aacrjournals.org/content/75/2/296.long
      4 https://link.springer.com/article/10.1007%2Fs00262-012-1378-2
      5 https://www.nature.com/articles/s41586-019-1805-z
      👍️0
      jondoeuk jondoeuk 4 years ago
      Hopefully, trials testing these improvements will start early next year https://www.fiercebiotech.com/biotech/gsk-taps-lyell-immunopharma-to-take-cell-therapy-to-next-level
      👍️0
      jondoeuk jondoeuk 4 years ago
      A new trial testing the NY-ESO-1 TCR-T cell therapy product [1] which either co-expresses a CD8a [2] or dnTGFßRII [2].

      Refs:
      1 https://clinicaltrials.gov/ct2/show/NCT04526509
      2 (Some of the R&D was conducting with ADAP) https://www.adaptimmune.com/our-company/perspectives/detail/1153/jon-silk-talks-about-our-next-generation-research
      👍️0
      MustBeTheTruth MustBeTheTruth 4 years ago
      Better Development Tools for a New Golden Era of Psychopharmacology

      https://www.thecannabisinvestor.ca/better-development-tools-for-a-new-golden-era-of-psychopharmacology/
      👍️0
      T695 T695 4 years ago
      Calls might sky rocket tomorrow
      👍️0
      T695 T695 4 years ago
      Calls for next month
      👍️0
      BottomBounce BottomBounce 5 years ago
      Trump promises Cincinnati rally that US will end AIDS epidemic and find a cure for childhood cancer 'very shortly'

      https://www.businessinsider.com/trump-cincinnati-promises-cure-cancer-and-aids-very-shortly-2019-8
      👍️0
      BottomBounce BottomBounce 5 years ago
      $GSK Democratic-run House approves its $3 trillion relief measure in vote late Friday https://www.marketwatch.com/story/next-coronavirus-aid-package-expected-to-become-reality-in-june-at-the-earliest-as-house-prepares-to-pass-its-bill-on-friday-2020-05-15?mod=mw_more_headlines
      👍️0
      BottomBounce BottomBounce 5 years ago
      Here's Why Investors Should Follow Sanofi $SNY and GlaxoSmithKline's $GSK New #Coronavirus #COVID19
      Collaboration


      https://www.fool.com/investing/2020/04/30/heres-why-investors-should-follow-sanofi-and-glaxo.aspx
      👍️0
      BottomBounce BottomBounce 5 years ago
      **** BREAKING HIV $GSK <<<< Drug giant GSK today declared a major breakthrough on a new HIV treatment it was trialling in patients that could prevent the spread of the disease. https://www.standard.co.uk/business/drug-giant-gsk-sees-major-breakthrough-on-hiv-treatment-a4442996.html
      👍️0
      Nebuchadnezzar Nebuchadnezzar 5 years ago
      GSK-especially now in current market turmoil $35 looks XTRA tasty
      👍️0
      BottomBounce BottomBounce 5 years ago
      Sci-B-Vac data is in December. That's the drug beating $GSK's Engerix-B

      The infection prevention rate for $VBIV 91.4% for Sci-B-Vac

      The infection prevention rate for $GSK 76.5% for Engerix-B
      👍️0
      BottomBounce BottomBounce 5 years ago
      $VBIV VBI Vaccines will collaborate with GlaxoSmithKline ( $GSK -2.8%) in a Phase 1/2a clinical trial evaluating its therapeutic vaccine candidate VBI-1901 in patients with recurrent glioblastoma (GBM) (brain tumor). It plans to add an additional arm to the open-label study to assess the combination of VBI-1901 and Glaxo's AS01B adjuvant that it uses in its Shingrix shingles vaccine.

      Part B of the trial will now be two arms, one evaluating VBI-1901 combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) and the other with AS01B, in 20 first-recurrent GBM patients. Enrollment of the first 10 participants should be initiated next quarter.
      👍️0
      BottomBounce BottomBounce 5 years ago
      $VBIV VBI Vaccines will collaborate with GlaxoSmithKline ( $GSK ) in a Phase 1/2a clinical trial evaluating its therapeutic vaccine candidate VBI-1901 in patients with recurrent glioblastoma (GBM) (brain tumor). It plans to add an additional arm to the open-label study to assess the combination of VBI-1901 and Glaxo's AS01B adjuvant that it uses in its Shingrix shingles vaccine.

      Part B of the trial will now be two arms, one evaluating VBI-1901 combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) and the other with AS01B, in 20 first-recurrent GBM patients. Enrollment of the first 10 participants should be initiated next quarter.

      https://seekingalpha.com/news/3498284-vbi-vaccines-teams-glaxo-therapeutic-cancer-vaccine-shares-10-percent
      👍️0
      BottomBounce BottomBounce 5 years ago
      $GSK and $VBIV VBI Vaccines teams up with Glaxo on therapeutic cancer vaccine https://seekingalpha.com/news/3498284-vbi-vaccines-teams-glaxo-therapeutic-cancer-vaccine-shares-10-percent
      👍️0
      Robbinhood101 Robbinhood101 5 years ago
      Watch this one go up with Tesaro approval.
      👍️0
      I Need Money I Need Money 5 years ago
      Certainly a great LONG term hold. ;)
      👍️0
      Don'tDrinkTheKoolAid Don'tDrinkTheKoolAid 5 years ago
      YIKES haha nice up tick with a great divvy.
      👍️0
      I Need Money I Need Money 5 years ago
      $41.99 now. :)
      👍️0
      Don'tDrinkTheKoolAid Don'tDrinkTheKoolAid 6 years ago
      Yep 39 now with 5% divvy I don't own it now :(!
      👍️0
      DewDiligence DewDiligence 6 years ago
      GSK, PFE form consumer-health JV: #msg-145552190.
      👍️0
      Dhubbard5 Dhubbard5 6 years ago
      I agree with your theory completely make total sense.
      👍️0
      debunker1 debunker1 6 years ago
      Novartis' Entresto is nothing more than an attempt to extend the patent life of Diovan (Valsartan). There is nothing to prove that Entresto is any better than the now generically available Valsartan.

      👍️0
      Don'tDrinkTheKoolAid Don'tDrinkTheKoolAid 7 years ago
      Buy anything below 36 not much down side risk.
      👍️0

      Your Recent History

      NYSE
      GSK
      GSK
      Delayed Upgrade Clock